GlycoMimetics (GLYC)
(Delayed Data from NSDQ)
$0.26 USD
-0.01 (-2.77%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.26 0.00 (-1.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
GlycoMimetics, Inc. [GLYC]
Reports for Purchase
Showing records 61 - 80 ( 158 total )
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Healthcare- Please Join Our Virtual 33rd Annual ROTH Conference on March 15 - 17th
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
4Q20 Results; Uproleselan Pivotal Trial Enrollment Expected to be Reached in 2H21; Lower PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
4Q20 Update - Liking the Focus, GLYC Remains One of Our Undervalued Gems
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Uproleselan Granted Breakthrough Therapy Designation in China for AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
GLYC & Apollomics Announce Uproleselan''s BTD for r/r AML in China
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
New OLE Results for Rivipansel in the Acute Treatment of Vaso-occlusive Crisis at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
ASH Highlights Game-Changing AML & Sickle Cell Data. Raising PT to $15.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Ahead of ASH, Dial into Our Sickle Cell KOL Call Tomorrow at 12PM ET
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
3Q20 Results; Phase 3 r/r AML Trial on Track; Multiple Data Presentations Expected at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
3Q20 Update - Multiple Shots on Goal With Momentum Set to Build at ASH
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z